

# Linus Vandekerckhove

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6511063/linus-vandekerckhove-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122  
papers

3,477  
citations

30  
h-index

55  
g-index

140  
ext. papers

4,418  
ext. citations

7  
avg, IF

5.11  
L-index

#	Paper	IF	Citations
122	Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens: Data from a real-life setting.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0262533	3.7	0
121	Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population.. <i>Vaccines</i> , <b>2022</b> , 10,	5.3	3
120	Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption.. <i>Cell Reports</i> , <b>2022</b> , 39, 110739	10.6	0
119	IRF7 and RNH1 are modifying factors of HIV-1 reservoirs: a genome-wide association analysis. <i>BMC Medicine</i> , <b>2021</b> , 19, 282	11.4	2
118	Organ-specific genome diversity of replication-competent SARS-CoV-2. <i>Nature Communications</i> , <b>2021</b> , 12, 6612	17.4	5
117	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , <b>2021</b> ,	50.5	16
116	Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1427-1438	35.1	11
115	PCIP-seq: simultaneous sequencing of integrated viral genomes and their insertion sites with long reads. <i>Genome Biology</i> , <b>2021</b> , 22, 97	18.3	11
114	Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	12
113	The Architecture of Circulating Immune Cells Is Dysregulated in People Living With HIV on Long Term Antiretroviral Treatment and Relates With Markers of the HIV-1 Reservoir, Cytomegalovirus, and Microbial Translocation. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 661990	8.4	5
112	Triplex digital PCR assays for the quantification of intact proviral HIV-1 DNA. <i>Methods</i> , <b>2021</b> ,	4.6	4
111	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , <b>2021</b> , 35, 2025-2033	3.9	0
110	Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2380-2393	5.1	2
109	In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. <i>Nature Communications</i> , <b>2021</b> , 12, 3727	17.4	10
108	A rare but devastating cause of twin loss in a near-term pregnancy highlighting the features of severe SARS-CoV-2 placentitis. <i>Histopathology</i> , <b>2021</b> , 79, 674-676	7.3	6
107	Single cell epigenetic visualization assay. <i>Nucleic Acids Research</i> , <b>2021</b> , 49, e43	20.1	1
106	Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 2971-2978	19.7	1

105	Motivations, barriers and experiences of participants in an HIV reservoir trial. <i>Journal of Virus Eradication</i> , <b>2021</b> , 7, 100029	2.8	1
104	Course and Survival of COVID-19 Patients with Comorbidities in Relation to the Trace Element Status at Hospital Admission. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	7
103	COVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	9.3	2
102	CD32CD4 memory T cells are enriched for total HIV-1 DNA in tissues from humanized mice. <i>IScience</i> , <b>2021</b> , 24, 101881	6.1	4
101	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	3
100	Benefits of antiretroviral therapy initiation during acute HIV infection. <i>Acta Clinica Belgica</i> , <b>2020</b> , 1-9	1.8	1
99	Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1311-1320	5.1	9
98	Underestimated effect of intragenic HIV-1 DNA methylation on viral transcription in infected individuals. <i>Clinical Epigenetics</i> , <b>2020</b> , 12, 36	7.7	10
97	Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription. <i>Journal of the International AIDS Society</i> , <b>2020</b> , 23, e25453	5.4	13
96	Emerging PCR-Based Techniques to Study HIV-1 Reservoir Persistence. <i>Viruses</i> , <b>2020</b> , 12,	6.2	10
95	On the whereabouts of SARS-CoV-2 in the human body: A systematic review. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1009037	7.6	73
94	Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , <b>2020</b> , 34, 707-718	3.5	16
93	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 628-639	5.1	5
92	Interferon-Mediated Long Non-Coding RNA Response in Macrophages in the Context of HIV. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
91	Evolution of Experimental Design and Research Techniques in HIV-1 Reservoir Studies: A Systematic Review. <i>AIDS Reviews</i> , <b>2020</b> , 22, 16-24	1.5	0
90	Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction. <i>Gut</i> , <b>2020</b> , 69, 191-193	19.2	82
89	Cytotoxic CD8+ T Cells Expressing CXCR5 Are Detectable in HIV-1 Elite Controllers After Prolonged Peptide Stimulation. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 622343	8.4	1
88	HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs. <i>Cell Host and Microbe</i> , <b>2019</b> , 26, 347-358.e7	23.4	62

87	Gold Nanoparticle-Mediated Photoporation Enables Delivery of Macromolecules over a Wide Range of Molecular Weights in Human CD4+ T Cells. <i>Crystals</i> , <b>2019</b> , 9, 411	2.3	19
86	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , <b>2019</b> , 393, 2428-2438	4.0	363
85	Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term non-progressors. <i>EBioMedicine</i> , <b>2019</b> , 41, 443-454	8.8	5
84	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age $\geq$ 50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 597-606	11.6	18
83	Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 3030-3034	5.1	7
82	Long non-coding RNAs and latent HIV - A search for novel targets for latency reversal. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224879	3.7	11
81	Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. <i>Journal of Virus Eradication</i> , <b>2019</b> , 5, 10-22	2.8	6
80	In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients. <i>Aids</i> , <b>2019</b> , 33, 387-398	3.5	5
79	Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1320-1328	11.6	11
78	Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients. <i>Acta Clinica Belgica</i> , <b>2018</b> , 73, 341-347	1.8	1
77	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e172-e180	7.8	23
76	Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance. <i>Retrovirology</i> , <b>2018</b> , 15, 1	3.6	16
75	Digital PCR as a tool to measure HIV persistence. <i>Retrovirology</i> , <b>2018</b> , 15, 16	3.6	51
74	Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199091	3.7	40
73	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , <b>2018</b> , 32, 205-215	3.5	3
72	In-depth validation of total HIV-1 DNA assays for quantification of various HIV-1 subtypes. <i>Scientific Reports</i> , <b>2018</b> , 8, 17274	4.9	17
71	Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy?. <i>Acta Clinica Belgica</i> , <b>2017</b> , 72, 198-200	1.8	1
70	HIV integration sites in latently infected cell lines: evidence of ongoing replication. <i>Retrovirology</i> , <b>2017</b> , 14, 2	3.6	37

69	Utility of integrated HIV-1 DNA quantification in cure studies. <i>Future Virology</i> , <b>2017</b> , 12, 215-225	2.4	3
68	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e486-e494	7.8	21
67	Fight fire with fire: Gene therapy strategies to cure HIV. <i>Expert Review of Anti-Infective Therapy</i> , <b>2017</b> , 15, 747-758	5.5	9
66	HIV Reservoir Characterization Symposium. <i>Journal of Virus Eradication</i> , <b>2017</b> , 3, 66-68	2.8	2
65	Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay. <i>Scientific Reports</i> , <b>2016</b> , 6, 36111	4.9	20
64	HIV-1 Vpr N-terminal tagging affects alternative splicing of the viral genome. <i>Scientific Reports</i> , <b>2016</b> , 6, 34573	4.9	7
63	Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 335	4	10
62	Highlights from the Conference on Retroviruses and Opportunistic Infections 2016: 22-25 February 2016, Boston, Massachusetts, USA. <i>Journal of Virus Eradication</i> , <b>2016</b> , 2, 124-30	2.8	
61	Diagnostic utility of droplet digital PCR for HIV reservoir quantification. <i>Journal of Virus Eradication</i> , <b>2016</b> , 2, 162-9	2.8	22
60	The use of HIV-1 integration site analysis information in clinical studies aiming at HIV cure. <i>Journal of Virus Eradication</i> , <b>2016</b> , 2, 175-6	2.8	1
59	Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005472	7.6	63
58	The Future of Digital Polymerase Chain Reaction in Virology. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 437-47	4.5	27
57	Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models. <i>Scientific Reports</i> , <b>2016</b> , 6, 38329	4.9	4
56	Minimal Requirements for Primary HIV Latency Models Based on a Systematic Review. <i>AIDS Reviews</i> , <b>2016</b> , 18, 171-183	1.5	3
55	Robust regression methods for real-time polymerase chain reaction. <i>Analytical Biochemistry</i> , <b>2015</b> , 480, 34-6	3.1	4
54	HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 3311-6	5.1	14
53	Th1/17 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral Therapy. <i>Journal of Virology</i> , <b>2015</b> , 89, 11284-93	6.6	64
52	During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ. <i>EBioMedicine</i> , <b>2015</b> , 2, 1153-9	8.8	29

51	Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 789-94	1.6	9
50	Reference gene validation for RT-qPCR, a note on different available software packages. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122515	3.7	140
49	Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123525	3.7	9
48	ddpcRquant: threshold determination for single channel droplet digital PCR experiments. <i>Analytical and Bioanalytical Chemistry</i> , <b>2015</b> , 407, 5827-34	4.4	74
47	Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses. <i>Open Forum Infectious Diseases</i> , <b>2015</b> , 2, ofv144	1	3
46	Accurate quantification of episomal HIV-1 two-long terminal repeat circles by use of optimized DNA isolation and droplet digital PCR. <i>Journal of Clinical Microbiology</i> , <b>2015</b> , 53, 699-701	9.7	19
45	Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. <i>ELife</i> , <b>2015</b> , 4, e09115	8.9	28
44	Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 1098-103	5.1	12
43	Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs. <i>Retrovirology</i> , <b>2014</b> , 11, 70	3.6	7
42	Dependence on the CCR5 coreceptor for viral replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 596-600	11.6	26
41	Accurate episomal HIV 2-LTR circles quantification using optimized DNA isolation and droplet digital PCR. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19674	5.4	3
40	The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19823	5.4	3
39	Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA. <i>PLoS ONE</i> , <b>2014</b> , 9, e85999	3.7	116
38	Factors associated with the continuum of care of HIV-infected patients in Belgium. <i>Journal of the International AIDS Society</i> , <b>2014</b> , 17, 19534	5.4	13
37	Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients. <i>Journal of Immunological Methods</i> , <b>2014</b> , 414, 1-10	2.5	15
36	Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 517-23	9.7	36
35	Antiretrovirals for HIV prevention: when should they be recommended?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2014</b> , 12, 431-45	5.5	1
34	Quantification of integrated HIV DNA by repetitive-sampling Alu-HIV PCR on the basis of poisson statistics. <i>Clinical Chemistry</i> , <b>2014</b> , 60, 886-95	5.5	32

33	Disseminated infection with <i>Mycobacterium tuberculosis</i> in a male immunocompromised patient. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 1777-9	9.7	4
32	Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. <i>AIDS Research and Therapy</i> , <b>2013</b> , 10, 3	3	20
31	Touchdown digital polymerase chain reaction for quantification of highly conserved sequences in the HIV-1 genome. <i>Analytical Biochemistry</i> , <b>2013</b> , 439, 201-3	3.1	12
30	Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. <i>Vaccine</i> , <b>2013</b> , 31, 3739-46	4.1	30
29	Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2013</b> , 8, e52563	7	76
28	Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e80259	3.7	10
27	Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. <i>Virology</i> , <b>2012</b> , 426, 7-11	3.6	41
26	Correlation of coreceptor usage and disease progression. <i>Current Opinion in HIV and AIDS</i> , <b>2012</b> , 7, 432-9	4.2	49
25	Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 205, 174-84	7	65
24	Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression. <i>PLoS ONE</i> , <b>2012</b> , 7, e50204	3.7	10
23	Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 265-72	5.1	21
22	Morbidity and mortality of bloodstream infections in patients with severe burn injury. <i>American Journal of Critical Care</i> , <b>2010</b> , 19, e81-7	1.7	57
21	Impaired hemoglobin scavenging during an acute HIV-1 retroviral syndrome. <i>Clinica Chimica Acta</i> , <b>2010</b> , 411, 521-3	6.2	13
20	High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. <i>Aids</i> , <b>2010</b> , 24, 669-73	3.5	28
19	Severe drug-induced liver injury associated with prolonged use of linezolid. <i>Journal of Medical Toxicology</i> , <b>2010</b> , 6, 322-6	2.6	45
18	Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections. <i>BMC Infectious Diseases</i> , <b>2010</b> , 10, 262	4	81
17	HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. <i>AIDS Research and Therapy</i> , <b>2010</b> , 7, 4	3	34
16	GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. <i>Current Opinion in Investigational Drugs</i> , <b>2010</b> , 11, 203-12		17



15	Maraviroc: perspectives for use in antiretroviral-naïve HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 1087-96	5.1	21
14	CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 50, 126-36	3.1	44
13	Impact of Delta 32-CCR5 heterozygosity on HIV-1 genetic evolution and variability--a study of 4 individuals infected with closely related HIV-1 strains. <i>Virology</i> , <b>2008</b> , 379, 213-22	3.6	13
12	Maraviroc: integration of a new antiretroviral drug class into clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 61, 1187-90	5.1	24
11	Abacavir hypersensitivity. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2514-5; author reply 2515-6	59.2	8
10	Fluconazole exposure and selection for <i>Candida non-albicans</i> . <i>Anesthesia and Analgesia</i> , <b>2008</b> , 107, 2091; author reply 2091-2	3.9	1
9	Lentiviral nuclear import: a complex interplay between virus and host. <i>BioEssays</i> , <b>2007</b> , 29, 441-51	4.1	34
8	Detection of drug resistance mutations as a predictor of subsequent virological failure in patients with HIV-1 viral rebounds of less than 1,000 RNA copies/ml. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 1254-60	19.7	12
7	Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. <i>PLoS Pathogens</i> , <b>2007</b> , 3, e47	7.6	96
6	Cellular co-factors of HIV-1 integration. <i>Trends in Biochemical Sciences</i> , <b>2006</b> , 31, 98-105	10.3	168
5	Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. <i>Journal of Virology</i> , <b>2006</b> , 80, 11498-509	6.6	144
4	Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. <i>Journal of Virology</i> , <b>2006</b> , 80, 1886-96	6.6	184
3	Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 25517-23	5.4	191
2	In-depth characterization of HIV-1 reservoirs reveals links to viral rebound during treatment interruption		1
1	In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia		1